Zika Virus Purified Inactivated Vaccine (ZPIV) Accelerated Vaccination Schedule Study

NCT ID: NCT02937233

Last Updated: 2018-08-23

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 36 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2016-12-08
• Study Completion Date: 2018-06-04

Brief Summary

This is a phase 1 trial of one or more administrations of Zika Virus Purified Inactivated Vaccine (ZPIV). The trial will be conducted under a placebo controlled, double-blind, randomized allocation of study product. There are four groups in the study. Each group is testing a different vaccine schedule.

Conditions

Zika

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: PREVENTION
• Blinding Strategy: QUADRUPLE

Study Groups

4 Week Schedule

Zika Purified Inactivated Vaccine 5 mcg (or placebo) IM at Week 0 and Week 4

Group Type: EXPERIMENTAL

Zika Virus Purified Inactivated Vaccine

Intervention Type: BIOLOGICAL

Placebo

Intervention Type: OTHER

2 Week Schedule

Zika Purified Inactivated Vaccine 5 mcg (or placebo) IM at Week 0 and Week 2

Group Type: EXPERIMENTAL

Zika Virus Purified Inactivated Vaccine

Intervention Type: BIOLOGICAL

Placebo

Intervention Type: OTHER

Single Vaccination Schedule

Zika Purified Inactivated Vaccine 5 mcg (or placebo) IM at Week 0 only

Group Type: EXPERIMENTAL

Zika Virus Purified Inactivated Vaccine

Intervention Type: BIOLOGICAL

Placebo

Intervention Type: OTHER

Interventions

Zika Virus Purified Inactivated Vaccine

Intervention Type: BIOLOGICAL

Placebo

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

1. Age 18-50 years old.

2. Ability and willingness to provide informed consent.

3. Assessment of understanding: completion of a questionnaire prior to first screening procedure; verbally demonstrate understanding of all questionnaire items answered incorrectly.

4. Available for the duration of the trial.

5. Good general health as shown by medical history, physical exam, and screening laboratory tests.

6. The following laboratory parameters:

• Hematology

• Hemoglobin ≥10.5 g/dL for women; ≥11 g/dL for men
• Absolute Neutrophil Count (ANC): ≥1000/mm3
• Platelets: 125,000 to 550,000/mm3
• Chemistry

• Creatinine: <1.1 x upper limit of normal (ULN)
• AST: <1.25 x ULN
• ALT: <1.25 x ULN
• Normal urinalysis

• Negative urine glucose.
• Negative or trace urine protein.
• Negative or trace urine hemoglobin (if trace hemoglobin is present on dipstick, a microscopic urinalysis within institutional range).

7. All female participants must be willing to undergo serum or urine beta human chorionic gonadotropin pregnancy tests at time points indicated in the Schedule of Procedures and must test negative prior to vaccination.

8. All sexually active males (unless anatomically sterile) must be willing to use an effective method of contraception (such as consistent condom use) from the day of first vaccination until Week 12.

9. If a woman of child-bearing potential, committed to use an effective method of contraception when sexually active with men until Week 12, including:

• Condoms (male or female) with or without spermicide.
• Diaphragm or cervical cap with spermicide.
• Intrauterine device.
• Hormonal contraception.
• Successful vasectomy in the male partner (considered successful if a woman reports that a male partner has [1] documentation of azoospermia by microscopy, or [2] a vasectomy more than 2 years ago with no resultant pregnancy despite sexual activity post-vasectomy).
• Not be of reproductive potential, such as having undergone hysterectomy, bilateral oophorectomy, or tubal ligation.

Exclusion Criteria

1. History of known flavivirus infection or previous receipt of flavivirus vaccine.

2. Positive serology for HIV-1, Hepatitis B surface antigen, or anti-hepatitis C virus antibodies prior to enrollment.

3. Planned travel to areas with active Zika virus transmission during the study period.

4. Recent (within 3 weeks) travel to an area with active Zika virus transmission.

5. Current or planned participation in another clinical trial of an experimental agent during the study period.

6. Pregnant or lactating.

7. Any condition, including any clinically significant acute or chronic medical condition, for which, in the opinion of the investigator, participation would not be in the best interest of the subject (eg, compromise the well-being) or that could prevent, limit, or confound the protocol-specified assessments.

8. Use of anticancer, antituberculosis or other medications considered significant by the investigator within the previous 6 months.

9. Receipt of live-attenuated vaccine within the previous 60 days or planned receipt within 60 days after vaccination with Investigational Product (within 14 days for live attenuated influenza vaccine [LAIV]); or receipt of other vaccine (e.g., influenza, pneumococcal), allergy treatment with antigen injections or tuberculin skin test within the previous 14 days or planned receipt within 14 days after vaccination with Investigational Product

10. Receipt of blood transfusion or blood-derived products within the previous 3 months.

11. Previous severe local or systemic reactions to vaccination.

12. History of splenectomy

13. History of seizure in the last 3 years (participants with a history of seizures who have neither required medications nor had a seizure for 3 years are not excluded)

14. Known autoimmune disease

15. Asthma other than mild, well-controlled asthma. Exclude participants who:

1. Use a bronchodilator (beta 2 agonist) daily, or

2. In the past year have (any of the following):

i. Had > 1 exacerbation of symptoms treated with oral steroids ii. Routinely used moderate to high dose inhaled corticosteroids (e.g., more than the equivalent of 250 mcg fluticasone; 400 mcg budesonide; 500 mcg beclomethasone; or 1000 mcg triamcinolone/flunisolide, as a daily dose) or theophylline iii. Needed emergency care, urgent care, hospitalization, or intubation for asthma c. Prophylactic bronchodilator use prior to exercise is not exclusionary

16. Diabetes mellitus type 1 or type 2, including cases controlled with diet alone. (Not excluded: history of isolated gestational diabetes.)

17. Thyroidectomy, or thyroid disease requiring medication during the last 12 months

18. Angioedema within the last 3 years if episodes are considered serious or have required medication within the last 2 years

19. Uncontrolled Hypertension:

1. If a person has been diagnosed with hypertension during screening or previously, exclude for hypertension that is not well controlled. Well- controlled hypertension is defined as blood pressure consistently ≤ 140 mm Hg systolic and ≤ 90 mm Hg diastolic, with or without medication, with only isolated, brief instances of higher readings, which must be ≤ 150 mm

2. If a person has NOT been diagnosed with hypertension during screening or previously, exclude for systolic blood pressure ≥ 150 mm Hg at enrollment or diastolic blood pressure ≥ 90 mm Hg at enrolment

20. Bleeding disorder diagnosed by a doctor (e.g. factor deficiency, coagulopathy, or platelet disorder requiring special precautions)

21. Malignancy (Not excluded: a participant with a surgical excision and subsequent observation period that in the investigator's estimation has a reasonable assurance of sustained cure or is unlikely to recur during the study period)

22. Psychiatric condition that compromises safety of the participant or precludes compliance with the protocol, specifically excluding persons with psychoses within the past 3 years, ongoing risk for suicide, or history of suicide attempt or gesture within the past 3 years

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 50 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Walter Reed Army Institute of Research (WRAIR)

FED

Sponsor Role: collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

Sponsor Role: collaborator

Kathryn Stephenson

OTHER

Sponsor Role: lead

Responsible Party

Kathryn Stephenson

Assistant Professor of Medicine

Responsibility Role: SPONSOR_INVESTIGATOR

Locations

Center for Virology and Vaccine Research Clinical Trials Unit, Beth Israel Deaconess Medical Center

Boston, Massachusetts, United States

Countries

United States

References

Stephenson KE, Tan CS, Walsh SR, Hale A, Ansel JL, Kanjilal DG, Jaegle K, Peter L, Borducchi EN, Nkolola JP, Makoni T, Fogel R, Bradshaw C, Tyler A, Moseley E, Chandrashekar A, Yanosick KE, Seaman MS, Eckels KH, De La Barrera RA, Thompson J, Dawson P, Thomas SJ, Michael NL, Modjarrad K, Barouch DH. Safety and immunogenicity of a Zika purified inactivated virus vaccine given via standard, accelerated, or shortened schedules: a single-centre, double-blind, sequential-group, randomised, placebo-controlled, phase 1 trial. Lancet Infect Dis. 2020 Sep;20(9):1061-1070. doi: 10.1016/S1473-3099(20)30085-2. Epub 2020 May 6.

Reference Type: DERIVED

PMID: 32618279 (View on PubMed)

Modjarrad K, Lin L, George SL, Stephenson KE, Eckels KH, De La Barrera RA, Jarman RG, Sondergaard E, Tennant J, Ansel JL, Mills K, Koren M, Robb ML, Barrett J, Thompson J, Kosel AE, Dawson P, Hale A, Tan CS, Walsh SR, Meyer KE, Brien J, Crowell TA, Blazevic A, Mosby K, Larocca RA, Abbink P, Boyd M, Bricault CA, Seaman MS, Basil A, Walsh M, Tonwe V, Hoft DF, Thomas SJ, Barouch DH, Michael NL. Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trials. Lancet. 2018 Feb 10;391(10120):563-571. doi: 10.1016/S0140-6736(17)33106-9. Epub 2017 Dec 5.

Reference Type: DERIVED

PMID: 29217375 (View on PubMed)

Other Identifiers

2016P000268

Identifier Type: -

Identifier Source: org_study_id